Eurofins - Optimed — Company Profile

Optimed 1, rue des Essarts 38610 Gières France Tel.: +33 (0)4 38 37 27 40 Fax: +33 (0)4 38 37 27 41 Website: http://www.optimed.fr/

OPTIMED Clinical Research is a Contract Research Organization (CRO), which offers its experience for phase I to phase IV studies and surveys.

Located in Grenoble, France, OPTIMED Clinical Research has led several hundreds of clinical studies on behalf of the pharmaceutical and agro-food industries, with the aid of :

• A 60-bed Clinical Pharmacology Unit for Phase I studies
• A 14-bed hospital based ClinPharm Unit in Lyon
• An experienced and stable clinical staff of physicians, study nurses, technicians and scientists.
• A monitoring team
• Data Management, Statistics and Medical Writing services

With its highly trained staff and up-to-date equipment, OPTIMED offers high standard quality services.

Making your constraints its own, we have set up an efficient organization for your studies : adherence to deadlines, cost control, and commitment to optimal quality.

Thanks to its experience, Optimed Clinical Research has developed expertise, in terms of organization, management, medical writing, regulatory management. Consequently, Optimed can support you at each step of your clinical trial.

In February 2006, Optimed joined the Eurofins group, worldwide leader in the bioanalytical testing market and in pharmaceutical services. This partnership allows Optimed to extend the range of services provided in drug development thanks to the synergy of the different companies of the group.


Source: Eurfins - Optimed

[Read more!]

IATEC — Company Profile

IATEC 199, rue Colbert Bâtiment Rochefort 59000 Lille France Tel.: +33 (0)3 20 54 27 68 Fax: +33 (0)3 20 50 93 41 Website: http://www.iatec.com/

Since its foundation in 1999, IATEC has focused on delivering high-quality research across the globe. Clinical trials are becoming increasingly complex. Rules and regulations change constantly; investigators are over-solicited; access to resources is often problematic. But we understand the scientific and regulatory challenges you are facing and we have been able to transform what would seem to be threats into opportunities. This is why IATEC is a real added value CRO for any of your projects.

IATEC Clinical Trial Services is an independent, full-service Contract Research Organization (CRO) that offers a comprehensive package of research services for the pharmaceutical industry. Working closely with our clients, we are committed to providing customized services that meet the required standards of quality – on time and within budget.

IATEC uses state-of-the art tools for data management, database construction and SAS^® for data validation and descriptive and inferential statistics. Each of our individual activities, from protocol development and writing, validation and production, to data management, statistical analyses and report writing, is carefully monitored to ensure that we are always able to provide good-quality services.

IATEC offers a set of tailor-made services that meet the international quality standards of regulatory bodies such as the ICH, CPMP and FDA. Our own system of quality control ensures that our standards are guaranteed at all levels.


Source: IATEC

[Read more!]

B Cell Design — Company Profile

B Cell Design Faculté de Médecine de Limoges 2, rue du Docteur Marcland 87025 Limoges Cedex France Tel.: +33 (0)5 55 43 59 37 Fax: +33 (0)5 55 43 59 37 Website: http://www.b-cell-design.com/

B Cell Design Development and production of humanised antibodies — a service provider activity, producing humanised IgA or IgG &mdash R&D activity for the development of humanised antibodies.

B Cell Design has been created in December 2007 and is a biotech lodged in Limoges university.


Source: B Cell Design

[Read more!]

Polyintell — Company Profile

Polyintell SAS 15, rue de la Carue 76000 Rouen France Tel.: +33 (0)2 35 52 24 30 Fax: +33 (0)2 35 52 24 30 Email: contact@polyintell.com Website: http://www.polyintell.com/

POLYINTELL is a private company having special competency on the development of innovative polymers for applications in life and pharmaceutical sciences.

Our expertise covers:

• Molecularly Imprinted Polymers from nano systems to monoliths
• Intelligent coating and hydrogel

Our aim is to create and develop innovative polymers that meet unsatisfied needs of life sciences and to help our clients in their problem solving.

POLYINTELL’s core strategy is to build on its internal expertise in the areas of intelligent polymer in order to provide customer with innovative polymers for their needs. Our investment in Research & Development is the key to our future growth.

History

POLYINTELL was founded in July 2004 based of skill of successful Scientifics in Upper-Normandy (France).

Thanks to its innovations, POLYINTELL is the winner of the Contest of Innovative and Technological Companies of the French Ministry of Research &Technology and the ESF, in 2004.

POLYINTELL was awarded for the third Special Prize of the national jury of the Contest of Innovative and Technological Companies of the French Ministry of Research&Technology in 2004.

We are supported by ANVAR, the incubator Acceval and the Regional Council.

Laboratories:
Sis IRCOF
Rue Lucien Tesnière
76130 Mont Saint Aignan
France


Source: Polyintell

[Read more!]

Holodiag — Company Profile

Holodiag Place Emile Blondel 76821 Mont Saint Aignan Cedex France Tel.: +33 (0)2 35 14 67 82 Fax: +33 (0)2 35 14 67 83 Email: contact@holodiag.com Website: http://www.holodiag.com/

Holodiag is a R&D company providing services for the development and the optimization of crystallization processes for fine chemical industries. The prevailing issues managed by Holodiag are post-screening polymorphism and enantiomer separation by crystallization. Holodiag's laboratory is available for analytical services : X-ray powder diffraction, DSC and TGA.

The Holodiag's research team, originally trained in the laboratory of Professor Gérard Coquerel, masters the following fields:

• Crystallization (small organic molecules)
• Thermodynamics of heterogeneous equilibria
• Phase diagrams
• Crystallography
• Molecular modeling

Source: Holodiag

[Read more!]

Toxem — Company Profile

Toxem SARL 73 rue Martainville 76000 Rouen France Tel.: +33 (0)6 19 35 73 11 Fax: +33 (0)2 32 10 23 02 Email: contact@toxem.com Website: http://www.toxem.com/

Established in 2008, TOXEM is an innovative biotechnology company specializing in high-throughput screening of mutagenicity.

Using conventional tests developed for HTS use , TOXEM helping with low cost to accelerate the pace of new molecules development in the pharmaceutical and cosmetical industries. TOXEM is also specializes in the development of new tests using the human TP53 tumor supressor gene.


Laboratories:
Faculté de médecine — Batiment de recherche
22, boulevard Gambetta
76183 Rouen cedex 1
France


Source: Toxem

[Read more!]

Biotech Finances — Company Profile

Biotech Finances 72, boulevard des Brotteaux 69006 Lyon France Tel.: +33 (0)4 78 24 35 20 Fax: +33 (0)4 86 68 91 27 Email: contact@biotech-finances.com Website: http://www.biotech-finances.com/

Editions Européennes de l'Innovation est un éditeur Européen qui diffuse une lettre d'information hebdomadaire des magazines et des produits spécialisés (cartographie) dans le secteur des biotechnologies et des sciences de la vie. Le produit phare de notre société d'édition est Biotech Finances dans sa version imprimée et Online.

Biotech Finances approche sur un angle économique et financier toutes les questions liées au développement du secteur des biotechnologies et plus largement des sciences de la vie. Notre lectorat cible est composé en majeure partie d'entreprises de biotechnologies orientées sur la santé et le développement de nouvelles thérapies et de nouveaux traitement de maladies, d'entreprises pharmaceutiques (big pharma et autres laboratoires) , d'investisseurs, business angel , fonds d'investissements, capital risque, spécialisés dans le secteur des biotech, d'institutionnels, de conseils juridiques, d'experts en développement, et de fournisseurs de services et fournisseurs de matériels. Nos articles traitent de recherche et développement, de nouveaux produits, médicaments, molécules, essai clinique et préclinique avec leur différentes phases, de financements et pratiques financières, de levées de fonds, augmentation de capital, prise de participations, d'IPO (introductions en bourse) de propriété industrielle, brevets, agréements en Europe (EMEA) et aux Etats-Unis (FDA), de partenariats, co-développement, licensing (in licensing /out licensing) qui permettent l'épanouissement et la croissance des sociétés de biotech. Biotech Finances aborde également les questions boursières avec son propre indice boursier quotidien construit à partir des 14 valeurs françaises de biotech introduites en bourse sur Euronext.

Tous les articles et archives de biotech finances sont accompagnés d'encadrés consacrés au business partnering ou partenariat d'affaires qui font le point sur les réseaux d'affaires ( conseils, experts, avocats, banques, pi, partenaires juridiques institutionnels, industriels etc.) et les opportunités de développements des entreprises de biotechnologie citées (maladies, candidat médicament, molécules, licensing, recrutement, investissement, immobilier).


Source: Biotech Finances

[Read more!]

Institut Rosell — Company Profile

Lallemand SAS 19, rue des Briquetiers BP 59 31702 Blagnac Cedex France Tel.: +33 (0)5 62 74 55 55 Fax: +33 (0)5 62 74 55 00 Email: human@lallemand.com Website: http://www.institut-rosell.com/

Institut Rosell is the Human Health and Nutrition Division of the Canadian-based Lallemand Group. A pioneer in probiotic applications since 1934, Institut Rosell's mission is to study, develop and produce probiotic solutions to help maintain and restore people's health and well-being.

Today, Institut Rosell concentrates its research efforts on the scientific and clinical documentation of its probiotics strains and formulations developed for their health benefits, including gastrointestinal, the immune system, women's health and children's health. Thanks to branch offices in Europe, North America and Asia, these products are distributed worldwide, either under Institut Rosell's own trademark, or via major players within the food supplement and pharmaceutical industries focused on consumer healthcare.


Source: Institut Rosell

[Read more!]

Hepartex — Company Profile

Hepartex 141, bureaux de la Colline 92213 Saint-Cloud France Tel.: +33 (0)1 46 02 13 15 Fax: +33 (0)1 46 02 48 66 Email: hepartex@hepartex.com Website: http://www.hepartex.com/

A unique global service from bulk Active Pharmaceutical Ingredients through to Marketing Authorisations and Finished Dosage Forms in synergy with our sister-company Venipharm.

Company profile

Since 1977 HEPARTEX has been marketing and distributing bulk Active Pharmaceutical Ingredients throughout France and Europe, in cooperation with the best International and fully compliant manufacturers for Human, Animal Health and Nutritional Industries.

Our basic philosophy has always been to develop a successful long term partnership between our Manufacturers and Clients.

Our knowledge and our capacity to adapt quickly to the changing expectations of the market mean that we are proud to count the World’s leading pharmaceutical companies amongst our customers.

With HEPARTEX you benefit from:

— The flexibility of an independent and strongly client-oriented structure.

— Technical and commercial expertise: our highly committed and experienced team is made up exclusively of chemists and pharmacists, with more than 25 years experience in the International market.

— A unique HEPARTEX / VENIPHARM offer, based on our ability to provide a global service focusing on individual requirements:

— Supply of active ingredients    — Registration dossiers    — Marketing Authorisations    — Access to finished dosage forms

Expertise & competence

A guarantee of efficient and tailored services to contribute to the success of our partners:

Hepartex is a marketing and distribution company operating as the link between the API producers and the pharmaceutical industry. Hepartex offers a tailor-made service, totally transparent with respect to both pharmaceutical companies and suppliers, whilst guaranteeing absolute confidentiality.

Marketing & Distribution Services:

— Identify the projects and business opportunities, by maintaining our close and regular contacts with our clients from R&D to logistic departments.
— Anticipate the changing market conditions and customer demands.
— Supply and distribute APIs from manufacturers to end users through a reliable, efficient and flexible supply chain: order — delivery — invoicing (in accordance with GDP regulation).

Technical & Regulatory Services:

— Evaluate patents together with external experts.
— Provide a close and continuous scientific monitoring between our manufacturers and our clients at all stages of product life cycle.
— Assist and advise our partners in compiling and filing technical documentation. (EDMF, COS….).

Custom Synthesis & Outsourcing:

— Select manufacturers able to develop custom-made synthesis for products not available on the market. (Provision of quantities from kilo and pilot scale to cGMP production)
— Research specific products through our large worldwide network of suitable producers to find the most appropriate match to the requirements of the pharmaceutical companies.
— Strive to achieve strong, long term International partnerships with major world producers: development of new products in liaison with R&D departments, technological and commercial monitoring.


Source: Hepartex

[Read more!]

Seppic — Company Profile

SEPPIC SA Tour Kupka C 7, boulevard Franck Kupka 92039 Paris - La Défense Cedex France Tel.: +33 (0)1 55 91 57 00 Fax: +33 (0)1 55 91 50 50 Email: info.seppic@airliquide.com Website: http://www.seppic.com/

SEPPIC currently has over 600 staff world-wide. Together, they are creating, developing and promoting innovative speciality chemical and biological products designed to meet the requirements of a wide range of markets including cosmetics, human health, animal health, nutrition, textiles, paper, fertilisers, lubricants, drilling, detergents, optical cables, glass, building, resins, plastics and polymers, paints and inks. SEPPIC offers its customers a wide range of high performance and innovative products.

SEPPIC is a company based within the international Air Liquide group. The state of the art ressources of Air Liquide allow SEPPIC to create the products needed in tomorrow's markets.

SEPPIC has widely recognised international expertise dedicated to ensuring customer satisfaction offering made-to-measure services, with the aim of Total Quality, to meet the economic challenges of the 21st century.

R&D, Marketing

Research lies at the heart of our company. We have brought our Research, Development and Marketing departments together so that our research and development is in touch with market trends.

This enables us to offer tools and services able to meet rapidly changing requirements.

Control over the design, the application and the use of our speciality chemical and biological products are essential for developing our markets.

The Castres Research Centre places its science and services at the service of customers to develop products for the future.

Over 80 research workers apply their expertise to synthesising chemical and biological products and improving the performance of our speciality chemicals, in particular for the beauty, medicine, health and hygiene markets as well as special applications for glass, lubricants, plastics and polymers, paper and textiles.

SEPPIC's research is also based on collaboration with public and private research organisations such as CNRS, INRA, INSERM and AFSSA. These joint research projects enable SEPPIC to respond more accurately and more quickly to meet the market requirements for technical performances.

Quality

The quality of products and services, environment, health and safety issues have been central to SEPPIC's strategy since 1989.

Its Total Quality objective is based on continual staff training and staff motivation and has clearly defined aims: respect for its customers, the environment and its staff and compliance with regulations.

Quality: always aiming to improve customer satisfaction while listening to them.

SEPPIC is certified to ISO 9001 to ensure control over all aspects from safety to use of its products. The "processus" management according to V 2000 is underway.

— Quality policy and specific improvement objectives
— Co-operation with suppliers, sub contractors and customers
— Improving the reliability of processes and production equipment
— Continual improvement of manufacturing practices

Health and Safety: objective "zero accidents"

— Procedures, audits, objectives and annual reports
— Motivation, training and preventive education
— Daily safety training
— Control over products used and the risks they represent
— Appropriate work methods and means of protection

Environment: protection of our natural environment

The environment is of major concern to SEPPIC:

— ISO 14001 certification mid 2000
— Control and reduction of liquid waste and pollutant gases
— Studies of waste and waste treatment
— Studies of risks and prevention of technological risks
— Product life cycle environmental accounting

Improvement of good manufacturing and responsible care practises is a permanent concern.


Other locations in France:

SEPPIC has two production subsidiaries in France and a new subsidiary in Antwerp, Belgium.
Each has its own range of speciality chemicals with production management systems controlling quality, productivity and total traceability.
As part of the Total Quality policy, Good Manufacturing Procedures are gradually being introduced in the various units.

SEPIPROD Castres
127, chemin de la Poudrerie
81108 Castres
France
Tel.: +33 (0)5 63 72 69 69
Fax: +33 (0)5 63 72 69 70

This unit covers an area of 8 hectares and manufactures 600 different products with an annual output of 30,000 tonnes. Castres produces mainly surfactants and surfactant-based products (sorbitan esters, alkylpolyglucosides, amides, betaines, etc.).

Additional products include, for example, polymers, pharmaceutical and veterinary excipients as well as glass frosting materials and special products for optical fibre cables.


Givaudan-Lavirotte
56, rue Paul Cazeneuve
BP 8344
Lyon 08
France
Tel.: +33 (0)4 78 61 55 00
Fax: +33 (0)4 78 61 55 94

The Givaudan-Lavirotte unit makes pharmaceutical and nutritional products and also provides services to the cosmetics industry. Its products are mainly used as ingredients for health products (mineral salts, nicotinates and undecylenates, protein surfactant complexes, etc.).


Source: Seppic

[Read more!]

Isochem — Company Profile

Isochem SA 12, quai Henri IV 75194 Paris Cedex 04 France Tel.: +33 (0)1 49 96 72 00 Fax: +33 (0)1 49 96 73 00 Website: http://www.isochem.fr/

ISOCHEM is a technology driven organization dedicated to the development of processes and the production of fine chemicals.

ISOCHEM offers its customers both a service of custom manufacturing, seamless throughout the life of their projects, and a catalogue of products derived from its core technologies and background.

ISOCHEM supplies its customers with high quality products and services in total compliance with the regulatory requirements and with a continuous focus on safety and sustainability.

ISOCHEM bases its growth on the value of its teams and trustful relations with all partners.

Profile

ISOCHEM offers exclusive or non exclusive product listings stemming from its basic technologies.

Boasting industrial scale expertise in multi-steps chemical synthesis processes, most of which bringing organic chemical reactions into play, ISOCHEM offers its customers its renowned skills in two specific fields: safe implementation of hazardous goods such as phosgene or hydrazines and particularly delicate aminoacids and peptide chemistry.

From process design to industrial operations, the whole service is ISO 9001 certified and complies with the most stringent quality standards in each field concerned.

The pharmaceutical-dedicated production sites are cGMP approved and undergo frequent audits by the American Food and Drug Administration.

Markets

For more than 30 years of partnership with the life sciences and speciality chemicals industries, ISOCHEM has developed a broad experience in the management of complex multistep synthesis from kilo laboratory to commercial scale production.
More over, ISOCHEM contributes to enhancing our quality of life, in a wide range of applications in the following markets:

Pharmaceutical:
ISOCHEM provides high quality services and products to pharmaceutical companies under cGMP or non cGMP requirements:
— Exclusive custom synthesis and development
— Generic Active Pharmaceutical Ingredients
— Pharmaceutical intermediates and active ingredients
— Excipient
— Aminoacid derivatives and Peptides

Cosmetics:
ISOCHEM supplies solutions and products to enhance your cosmetic project.
— Exclusive custom synthesis and development

Plant protection:
ISOCHEM has a long history relating to the development, scaling up, manufacture of molecules used in the Plant Protection sector. We are serving the major agrochemicals companies as well as smaller niche agrochemicals actors in the following segments:
— Exclusive custom synthesis and development
— Insecticides
— Fungicides
— Herbicides
— Plant growth regulators
— Biocides chemicals

Speciality intermediates:
ISOCHEM offers various chemicals for the Speciality Intermediates segments, these chemicals are using a wide range of technologies and industrial production scales.
— Exclusive custom synthesis and development
— Polymer chemical: ISOCHEM is offering intermediate used in the manufacture of organic peroxides, cross linking agent and monomer, polymer additives for polymer industry.
— Electronics: Production of Lithium battery electrolytes for mobil phones as well as various intermediates used in the liquid crystal, photoresists and LCD industries.

ISOCHEM is offering a range of scratch resistant varnishes with various applications from the protection of military aircraft windows, ski goggles to ophthalmic glasses.
— Paper Industry: ISOCHEM offers coating chemicals enhancing specific properties required by the customer.
— Imaging chemicals: Supply of molecules used in the manufacture of photographic, reprographic chemicals and thermal paper.


Source: Isochem

[Read more!]

Novasep — Company Profile

Groupe Novasep 82, boulevard de la Moselle BP 50 54340 Pompey France Tel.: +33 (0)3 83 49 71 30 Fax: +33 (0)3 83 49 71 40 Email: novasep@novasep.com Website: http://www.novasep.com/

Innovative and cost effective purification solutions and chemistry for the life-science industries.

St Maurice de Beynost Purification processes for industrial biotech products 5, chemin du Pilon St Maurice de Beynost 01708 Miribel France Tel.: +33 (0)4 72 01 27 27 Fax: +33 (0)4 72 25 88 99 Email: industrialbiotech@novasep.com Website: http://www.novasep.com/Novasep-Process/Site/site-applexion.asp Pompey Purification processes for pharmaceuticals Boulevard de la Moselle BP 50 54340 Pompey France Tel.: +33 (0)3 83 49 70 00 Fax: +33 (0)3 83 49 70 02 Email: pharma@novasep.com Website: http://www.novasep.com/Novasep-Process/Site/site-novasep.asp Brabois Purification processes for biopharmaceuticals 13, rue du bois de la Champelle 54500 Vandoeuvre-lès-Nancy France Tel.: +33 (0)3 83 49 70 00 Fax: +33 (0)3 83 49 70 02 Email: novasep@novasep.com Website: http://www.novasep.com/Novasep-Process/Site/site-bioprocess.asp

Le Mans HPAIs synthesis and purification Rue Démocrite 72000 Le Mans France Tel.: +33 (0)2 43 39 94 40 Fax: +33 (0)2 43 39 94 49 Email: seripharm@novasep.com Website: http://www.novasep.com/Novasep-Synthesis/Site/site-seripharm-lemans.asp Chasse/Rhône Exclusive synthesis services from early stage to commercial supply Route de Givors 38670 Chasse-sur-Rhône France Tel.: +33 (0)4 72 49 19 60 Fax: +33 (0)4 72 49 19 73 Email: finorga@novasep.com Website: http://www.novasep.com/Novasep-Synthesis/Site/site-finorga-chasse.asp Mourenx Exclusive synthesis services from early stage to commercial supply Avenue du Lac 64150 Mourenx France Tel.: +33 (0)5 59 60 79 00 Fax: +33 (0)5 59 60 79 49 Email: finorga@novasep.com Website: http://www.novasep.com/Novasep-Synthesis/Site/site-finorga-mourenx.asp

Source: Novasep

[Read more!]

Naturex — Company Profile

Naturex Site d'Agroparc BP 1218 84911 Avignon Cedex 9 France Tel.: +33 (0)4 90 23 96 89 Fax: +33 (0)4 90 23 73 40 Email: naturex@naturex.com Website: http://www.naturex.com/

Naturex offers a complete line of plant extracts with flavoring, coloring, antioxidant or nutraceutical properties.
These extracts are then integrated by our industrial customers into products for public consumption: food products (meat products, drinks, cooked meals…) or food supplements (tablets, capsules …).

Listed on the Paris Stock Exchange Market, Naturex has acquired the necessary means to enhance its internal and external growth.

From the purchasing of the vegetable raw materials and the development and quality control laboratories to the industrial equipment, Naturex controls all the stages of the manufacturing process.

With 90 percent of its activity abroad, Naturex is present commercially in the whole world through its own locations or its agents’ network.


Source: Naturex

[Read more!]

ZaCh System SA — Company Profile

ZaCh System SA Z.l. La Croix Cadeau BP 10079 49240 Avrillé France Tel.: +33 (0)2 41 96 61 61 Fax: +33 (0)2 41 42 76 55 Website: http://www.zachsystem.com/

Fine chemicals: Production and R&D site, commercial offices.

• Total production capacity of 200 cubic meters
• 3 independent production units
• Choice of reactors with capacities from 2,000-10,000 Liters
• 2 hydrogenators with a capacity of 4000 liters and pressure operation up to 12 bars
• Finishing and Separation Equipment encompassing Clean Room in each production area, Rotary, Pan, Filter Dryers, Freeze Drying, Spray Drying, Micronization, Milling and Sieving, and Blending

Source: ZaCh System

[Read more!]

Axyntis — Company Profile

Axyntis Group Bioparc 8, rue de la Croix Jarry 75013 Paris France Tel.: +33 (0)1 44 06 77 00 Fax: +33 (0)1 44 06 76 99 Email: contact@axyntis.com Website: http://www.axyntis.com/

Leading fine and specialty chemicals company, French-based, Axyntis independent group with its 350 employees offers a deep rooted technical experience — the history of dyes activity started in 1881 at Saint-Marcel and the history of fine chemicals in 1879 at Grasse under the name "Schmoller et Bompard" for perfumery. This group designs innovative chemical processes and offers project management in close relationship with its customers.

Axyntis group has two divisions. One is dedicated to dyes: Steiner. One is dedicated to fine chemicals: Axyntis fine chemicals. Each division has its specificity even if they share the same safety and environment policy as well as common services to develop synergies.

The dyes division, Steiner, is a synthetic dye producer since 1881. Dyes are formulated for petroleum, oils, paper, cardboard, leather, textile, wood, ink, plus various other applications. 80 people are working for Steiner in France, St Marcel, and produce 8000 tons of formulated products per year. Steiner R&D Laboratory — 10 people — formulates and develops new technologies for the future of our customers. Steiner customers are located in Europe, America, Africa, and in the entire Mediterranean Basin. Concerned by environment protection, Steiner is equipped with a water treatment station. Steiner is certified ISO 9001 and ISO 14001.

Steiner has also a branch based in UK under the name of Steiner UK which operates for customers locally and brings an internal second source to secure the supply chain of its European customers.

The fine chemicals division, Axyntis fine chemicals, along with capacity of 380 m³ under cGMP, is split in four different plants, each of them having its own specificity:

These plants are complementary and enable a safety supply chain solution to the customers including internal back up strategy:

• Orgapharm is designed for key advanced intermediates and APIs for Pharmaceuticals industry and LCD under exclusive relationship;
• Centipharm is designed for exclusive key intermediates and generic API with its own regulatory support (US and European DMF and CEP);
• All’Chem is designed for key intermediates for electronic, agro and specialty;
• Synthexim is designed for key intermediates for pharma chemicals.

Both Orgapharm and Centipharm bring in addition Ramp;&D centers and Pilot capabilities which make these two plants a "one stop shop" for customers with a unique place for efficient transition phase between R&D and production (process development; scale up).

The four plants are Seveso II and two of them are high level compliant: this reflects the ability to perform complex chemistry and specific reactions that require high level of technical competence and specialized know-how.

With a competitive cost structure and a business network extended recently in the US and Asia, Axyntis group offers the best balance between expertise in specific reactions, flexibility, cost efficiency and time management for projects of innovative and fast growing companies in Europe, North America and Asia.

Orgapharm Rue du Moulin de la Canne 45300 Pithiviers France Tel.: +33 (0)2 38 06 20 00 Fax: +33 (0)2 38 30 24 24 Plant Director: Emmanuel Huet (emmanuel.huet@axyntis.com) A polyvalent plant with high level cGMP compliance in both intermediate and API productions.

Centipharm Chemin de la Madeleine BP 45249 06131 Grasse Cedex France Tel.: +33 (0)4 93 70 01 32 Fax: +33 (0)4 93 70 05 65 Works manager: Guy Duquesne (guy.duquesne@axyntis.com) Fine organic chemical products with both high added value and high level GMP compliance.

All'Chem Rue Marceau BP 577 03108 Montluçon France Tel.: +33 (0)4 70 03 75 25 Fax: +33 (0)4 70 03 08 79 Plant Director: Pascal Feniet (pascal.feniet@axyntis.com) For high production volumes and long-lasting production campaigns of chemical specialties.

Synthexim Rue des Mouettes ZI des Dunes 62100 Calais France Tel.: +33 (0)3 21 96 85 00 Fax: +33 (0)3 21 96 04 25 Plant Director: Bertrand Cazin (bertrand.cazin@axyntis.com) A 24/7 production plant operating in a five shifts system to supply your fine organic chemicals.

Steiner SAS 9, route de Rouen 27950 Saint-Marcel France Tel.: +33 (0)2 32 64 58 40 Fax: +33 (0)2 32 64 58 49 Plant Director: Laurent Choumery (laurent.choumery@axyntis.com) Our industrial mastering: a response to all your colouring needs.

Source: Axyntis

[Read more!]

Gattefossé — Company Profile

Gattefossé 36, chemin de Genas BP 603 69804 Saint-Priest France Tel.: +33 (0)4 72 22 98 00 Fax: +33 (0)4 78 90 45 67 Website: http://www.gattefosse.fr/

Created in 1993, Gattefossé France has, since the beginning, shown its ability to accompany its customers well beyond the call of a raw material distributor.

Alert the to growing demand from the cosmetologists and pharmacists for support during their creative processes, the company insists upon the importance of associating ingredients from Gattefossé and LIBiol, Noveon and Mitsubishi, to current market trends.

Under the direction of Thierry Magnet, 20 people from various backgrounds live to the rhythm of development projects from every French cosmetic and pharmaceutical trademarks. This dynamic team works hard to satisfy the needs of its clients, researchers and marketers.

Their priority? Transform emerging concepts into purposeful products. From idea to realization, conception is accelerated and optimized.
"Solutions prescriber", Gattefossé France sets itself apart through its singular processes where strategic intelligence leaves little room for luck or hesitations.

The Company Today

Gattefossé is a leading provider of specialty ingredients and formulation solutions to the Health and Personal Care industries worldwide.
Founded over a century ago by pioneering scientists, the company possesses in-depth know-how in the areas of biological extraction and oleochemistry.

Today, Gattefossé’s products are widely used to improve the delivery of difficult actives in applications ranging from solubility enhancement to modified release (immediate or sustained). Product applications include solutions for oral, topical, and suppository dosage forms.

The company’s success and multinational status today is the result of its commitment over the years to quality of service aimed at meeting and surpassing customer expectations.

Combining scientific and technological advances, Gattefossé has consistently transformed natural ingredients into products that meet the formulation challenges of rapidly developing markets.

Headquartered in France, the Gattefossé Group has a service and distribution network that reaches over 50 countries across five continents.

History

Gattefossé was founded in 1880 in France by Louis Gattefossé, an entrepreneur who believed in building strong relationships with his customers. He nurtured "curiosity" a quality that was to prove precious for the future of his enterprise and family.

Later, René-Maurice Gattefossé, creator of perfumes and scents and inventor of aromatherapy took the realm of the company. A scholar and a great communicator, he brought to the company a scientific meticulousness that was only matched by his progressive thinking.

In succession, Henri-Marcel Gattefossé widened the scope of the company activities to include biological extracts. An executive with passion for science, he collaborated closely with researchers in hospitals and universities around the world.

A man of scientific contacts, Henri-Marcel would later create Académie des Alpilles, also known as Journées Galéniques de St-Rémy. Forty years later, this institution remains active and has gained international stature.

Emile Mahler, a creative engineer and chemist joined the company in 1937. In the years to come, his work on lipids, emulsion technologies, and their applications in formulation development were to have profound impact upon the company's direction and long-term development.


Source: Gattefossé

[Read more!]

PCAS Biosolution — Company Profile

PCAS Biosolution SAS 70, allée Graham Bell Parc Georges Besse 30000 Nîmes France Tel.: +33 (0)4 66 27 29 21 Fax: +33 (0)4 66 27 29 20 Email:info@pcas-bio.com Website: http://www.pcas-bio.com/

PCAS Biosolution is a joint-venture created in 2006 by PCAS and Protéus with headquarters in Longjumeau, France and operating facilities located in the South of France. PCAS Biosolution aims at providing our customers all the value drivers of integrating biocatalysis into chemical processes.

Headquarters
23, rue Bossuet
Z.I. de la Vigne Aux Loups
91160 Longjumeau
France


Vision & Strategy

PCAS Biosolution integrates chemistry and biotechnology to provide a unique and exclusive offering to the pharmaceutical industry.

The Company combines and integrates multidisciplinary expertise, proprietary technologies and multi-scale production capabilities in both chemistry and biotechnology. We focus on the synthesis of APIs, intermediates and building blocks using chemo-biocatalytic manufacturing routes. Biocatalytic steps provide scalability, versatility and a high chemo-, regio-, stereo- and enantioselectivity.

Benefits include the ability to produce complex intermediates and APIs using scalable routes, reduce manufacturing costs, improve productivity, reduce byproducts and develop competitive green chemistry process.

We are committed to be your quality partner for the development, manufacture and long term supply of your intermediates and APIs using the optimal chemo-biocatalytic routes that meet your specifications of quantity, time, quality and targeted price.

Mission

Our mission is to provide significant value to drug developers by designing, developing and implementing new cost-effective and scaleable manufacturing routes to APIs and intermediates which combine both chemistry and biotechnology. The company aims at creating brand new routes to innovative products or at improving the manufacturing process of currently marketed products. Our focus is on reducing the number of manufacturing steps, decreasing by-products, avoiding hazardous chemicals, using lower cost raw material, enhancing purity and process enantio-selectivity, increasing conversion rate and improving overall yield, energy consumption and performance.

More value also means more Industrial Property: biocatalysts and processes developed are generally proprietary, thus providing opportunities to the drug developers to reinforce and extend the lifetime of their existing intellectual property.

With PCAS Biosolution, your projects will benefit from a unique, comprehensive and integrated chemo-biocatalytic R&D, industrial and regulatory platform.


Source: PCAS Biosolution

[Read more!]

PCAS — Company Profile

PCAS BP 181 23, rue Bossuet Z.I. La Vigne aux Loups 91160 Longjumeau France Tel.: +33 (0)1 69 09 77 85 Fax: +33 (0)1 69 74 81 04 Email:infopharma@pcas.fr Website: http://www.pcas.fr/

PCAS is the special partner of pharmaceutical laboratories for the development, production and market launch of bulk APIs.

PLANTS:

Usine de Bourgoin
15, avenue des frères-Lumière
38300 Bourgoin-Jallieu
France
Tel.: +33 (0)4 74 93 63 33
Fax: +33 (0)4 74 28 29 98

Usine de Couterne
Route de Lassay
61410 Couterne
France
Tel.: +33 (0)2 33 37 50 20
Fax: +33 (0)2 33 37 50 21

Usine de Limay
19, route de Meulan
78520 Limay
France Tel.: +33 (0)1 34 78 87 87
Fax: +33 (0)1 30 92 03 46


EXPANSIA

Headquarters
BP 181
23, rue Bossuet
ZI de la Vigne-aux-Loups
91160 Longjumeau
France
Tel.: +33 (0)1 69 09 77 85
Fax: +33 (0)1 64 48 23 19

Plant
Route d’Avignon
30390 Aramon
France
Tel.: +33 (0)4 66 57 01 01
Fax: +33 (0)4 66 57 01 48


SOCIÉTÉ BÉARNAISE DE SYNTHÈSE

Headquarters
BP 181
23, rue Bossuet
ZI de la Vigne-aux-Loups
91160 Longjumeau
France
Tel.: +33 (0)1 69 09 77 85
Fax: +33 (0)1 64 48 23 19

Plant
Plateforme Sobegi
Pôle 4
Avenue du Lac /R.D.281
64150 Mourenx
France
Tel.: +33 (0)5 59 92 75 33
Fax: +33 (0)5 59 92 75 31


VLG CHEM

Headquarters
BP 181
23, rue Bossuet
ZI de la Vigne-aux-Loups
91160 Longjumeau
France
Tel.: +33 (0)1 69 09 77 85
Fax: +33 (0)1 64 48 23 19

Plant
35, avenue Jean-Jaurès
92390 Villeneuve-La-Garenne
France
Tel.: +33 (0)1 46 85 91 91
Fax: +33 (0)1 46 85 91 61


PROTEUS

Headquarters
70, allée Graham Bell
Parc Georges Besse
30000 Nîmes
Tel.: +33 (0)4 66 70 64 64
Fax: +33 (0)4 66 70 64 60
www.proteus.fr


Source: PCAS

[Read more!]

FDA’s first-cycle review of Dysport® to be completed by year-end: US launch of Dysport® on track

Paris (France), 30 September 2008 — Ipsen (Euronext; IPN) today announced that the U.S. Food and Drug Administration (FDA) provided notification that the Prescription Drug User Fee Act (PDUFA) action date for Dysport^® (botulinum toxin of type A) Biologics License Application (BLA) for the treatment of patients with cervical dystonia has been extended to no later than 28 December 2008. This regulatory decision will not impact the anticipated company launch plan timing.

The FDA has not requested additional safety or clinical studies for review.

In accordance with first-cycle review of new therapies, the FDA requested a Risk Communication Plan in order to ensure safe use of the product in treating patients. The Agency has therefore extended the PDUFA action date to no later than December 28, 2008, in order to finalize the review of those items.

"We are assembling the requested information from the dossier, in close coordination with the FDA," said Stéphane Thiroloix, Executive Vice-President, Corporate Development of the Ipsen Group. "We strongly believe that appropriate recommendations through vehicles like patient medication guide and appropriate direct communications to attending physicians are the way forward to enhance and further define information already available in the package inserts. In meeting the Agency’s information need, Ipsen also addresses a patient-care imperative.".

Dysport^® has been granted orphan product status by the FDA as a treatment for cervical dystonia, an orphan disease in the United States. The BLA submission relies on data from two pivotal Phase III studies performed in the United States and abroad totalling 252 patients followed-up for up to 12 treatment cycles, in addition to substantial patient exposure in other clinical studies in cervical dystonia.

The timeline for the US commercialisation of Dysport^® is unchanged from original plans, and the US neurology team is preparing diligently for the launch.

Used in patient care in the United Kingdom since 1991, Dysport^® has marketing authorizations in more than 70 countries. Patient exposure is estimated to be above two million single treatment cycles representing more than 600 000 patients/year of treatment. Dysport^® is approved outside the US for eight indications including cervical dystonia (involuntary distorsions of the neck).


About Dysport^®

The active substance in Dysport^® is a botulinum neurotoxin type A complex, which acts at the level of the neuromuscular junction in the targeted muscle. Dysport®, Ipsen’s botulinum toxin type A, is a neuromuscular blocking toxin which acts to block acetylcholine release at motor nerve ends and reduces muscular spasm. It was initially developed for the treatment of movement disorders such as cervical dystonia (a chronic condition in which the neck is twisted or deviated), blepharospasm (involuntary eye closure), hemifacial spasm and various forms of muscle spasticity, including post-stroke arm spasticity, spasticity of the lower limbs (calf) in adults and children with cerebral palsy.

About Ipsen

Ipsen is an innovation-driven international specialty pharmaceutical group with over 20 products on the market and a total worldwide staff of nearly 4,000. Its development strategy is based on a combination of specialty products, which are growth drivers, in targeted therapeutic areas (oncology, endocrinology and neuromuscular disorders), and primary care products which contribute significantly to its research financing. The location of its four Research & Development centres (Paris, Boston, Barcelona, London) and its peptide and protein engineering platform give the Group a competitive edge in gaining access to leading university research teams and highly qualified personnel. More than 700 people in R&D are dedicated to the discovery and development of innovative drugs for patient care. This strategy is also supported by an active policy of partnerships. In 2007, Research and Development expenditure was about €185 million, in excess of 20% of consolidated sales, which amounted to €920.5 million while total revenues amounted to €993.8 million. Ipsen’s shares are traded on Segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150). Ipsen’s shares are eligible to the "Service de Règlement Différé" ("SRD") and the Group is part of the SBF 120 index. For more information on Ipsen, visit our website at www.ipsen.com.

Ipsen Forward-Looking Statements

The forward-looking statements, objectives and targets contained herein are based on the Group’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. Moreover, the targets described in this document were prepared without taking into account external growth assumptions, as announced on June 5, 2008 and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by the Group. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties. The Group does not commit nor gives any guarantee that it will meet the targets mentioned above. Furthermore, the Research and Development process involves several stages at each of which there is a substantial risk that the Group will fail to achieve its objectives and be forced to abandon its efforts in respect of a product in which it has invested significant sums. Therefore, the Group cannot be certain that favourable results obtained during pre-clinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. The Group expressly disclaims any obligation or undertaking to update or revise any forward looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. The Group’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers.


Source: Ipsen

[Read more!]

Minakem — Company Profile

Minakem SAS 145, chemin des Lilas 59310 Beuvry-la-Forêt France Tel.: +33 (0)3 20 64 68 30 Fax: +33 (0)3 20 64 68 31 Email: contact@minakem.com Website: http://www.minakem.com/

Minakem is a manufacturer of fine chemicals, advanced cosmetology, pharmaceutical intermediates and active pharmaceutical ingredients (APIs).

We offer an independent partnership providing fine services for the life science industries.

Today, the largest pharmaceutical and biopharmaceutical companies are routinely utilizing Minakem as their approved partner, developer and manufacturer for high-profile, proprietary compounds.

MINAKEM core business activities are :

— Synthesis of Starting Materials for the fine chemical industry in dedicated facilities with cost-effective processes, within or out of cGMP guidelines when not required.

— Custom Manufacturing of Key Intermediates for the pharmaceutical industry with finishing stages in qualified cGMP plants

— APIs manufacturing under cGMP guidelines

History

1952: Company’s foundation by Mr. Claude Dufour in the western suburb of Paris (Boulogne under the name of "Laboratoires du Bois de Boulogne" and renamed later on as SEAC.

1962: SEAC moves its industrial operations to its current location north of France in Beuvry la Foret near Lille.

1988: SEAC becomes a 100% subsidiary of the French company CFPI.

1998: CFPI is acquired by Nufarm Limited, the Australian chemical group, further positioning itself in the agrochemical market. SEAC remains managed as a stand-alone company within the group, focusing on fine chemicals.

2005: Minakem Holding SAS acquired all the assets related to the custom synthesis, including the R&D laboratories, pilot plant and manufacturing resources from SEAC.

Operating under the name of Minakem SAS, headquarters were relocated to Beuvry la Forêt. The company is privately owned.

Minakem establishes Minakem, L.L.C in the United States (New Jersey). This new affiliate manages the groups North-American business and support its development within the domestic market.


Source: Minakem

[Read more!]

Endotis Pharma — Company Profile

Endotis Pharma Parc Eurasanté 70, rue du Docteur Yersin 59120 Loos France Website: http://www.endotis.com/

ENDOTIS PHARMA is a specialty pharma company dedicated to the discovery and development of small-glyco drugs (SGDs) for applications in thrombosis and oncology. These SGDs are analogues of glycosaminoglycans, the core field of expertise of Endotis' scientists. Endotis Pharma has built a well-balanced portfolio of pre-clinical and clinical stage compounds.


Corporate Profile

Incorporated in 2003, Endotis Pharma is a specialty pharma company dedicated to the discovery and development of small-glyco drugs (SGDs) for applications in thrombosis and oncology.
These SGDs are analogues of glycosaminoglycans, the core field of expertise of Endotis' scientists. Proof of concept has already been obtained with oligosaccharides in thrombosis (veinous and arterial cardiovascular diseases) and oncology, another promising therapeutic field.
Endotis Pharma has built a well-balanced portfolio of pre-clinical and clinical stage compounds (either in-licensed or generated by the company's own R&D programmes) and currently has 28 employees (including 14 PhDs/MDs) based in Paris and Lille (France).
To date, Endotis Pharma has raised a total of 34 million euros with Sofinnova Partners (France), The Wellcome Trust (UK), Endeavour Vision (Switzerland) and NIF SMBC (Japan).

Business Strategy

Endotis business strategy consists in:
— Developing a de-risked portfolio of antithrombotic compounds from pre-clinical to clinical stages
— Leveraging its unique small-glyco drug engine in oncology

Partnering strategy:
Endotis will seek to partner antithrombotic drugs when proof of concept in man is reached, and to partner its oncology platform after proof of concept in animals is reached.
Endotis will also study other partnering opportunities.

In order to guide Endotis development, the company has built a strong management team under the leadership of Charles Woler, and assembled a Scientific Advisory Board and a Clinical Advisory Board with worldwide renowned in Glycoscience and Thrombosis.


Source: Endotis Pharma

[Read more!]

Ipsen announces the filing of Decapeptyl® 6-month formulation for the treatment of locally advanced or metastatic prostate cancer in Europe

The filing of the new Decapeptyl®1 6-month formulation is in accordance with Ipsen’s regulatory timeline

Paris (France), 25 September 2008 — Ipsen (Euronext: FR0010259150; IPN) today announced the start of the filing process in Europe of the 6-month sustained release formulation of Decapeptyl^®, a luteinizing hormone releasing hormone agonist (LHRHa) developed by Debiopharm for the treatment of locally advanced or metastatic hormone-dependent prostate cancer.

On 31 October 2007, Ipsen exclusively in-licensed from Debiopharm know-how and new patent applications for the commercialization rights of the new 6-month formulation of Decapeptyl^® (triptorelin pamoate) in the world excluding North America, and some other countries (Sweden, Israel, Iran and Japan).

¹1depending on the countries, Ipsen commercialises Decapeptyl^® under different brand names (Diphereline^®, Pamorelin^®, Arvekap^®)

About Decapeptyl^®

Decapeptyl^® is a peptide formulation for injection that was initially developed by Debiopharm and continues to be used mainly in the treatment of advanced metastatic prostate cancer. Additional indications developed subsequently include the treatment of uterine fibroids (a benign tumour of muscle tissues in the uterus), endometriosis (proliferation of endometrial tissue, the mucous membrane that lines the uterine wall outside the reproductive tract) prior to surgery or when surgery is not deemed appropriate, as well as early onset puberty and female infertility (in vitro fertilisation). Decapeptyl^® is available in monthly or quarterly sustained-release formulations, as well as a daily formulation. The active substance in Decapeptyl^® is triptorelin, a decapeptide analogue of GnRH (Gonadotrophin Releasing Hormone), a hormone secreted by the hypothalamus, which initially stimulates the release of pituitary gonadotrophins (hormones produced by the pituitary gland), which in turn control hormonal secretions by the testes and ovaries. Decapeptyl^® is mainly indicated in the treatment of locally advanced or metastatic prostate cancer. In this indication, Decapeptyl^® temporarily increases the concentration of testosterone and dihydro testosterone, but continuous administration paradoxically leads to a reduction in plasmatic testosterone concentration. After two to three weeks of treatment, testosterone is reduced to levels below the castration threshold, thereby depriving prostate tumours of one of the main hormones promoting tumour development. Decapeptyl^® was initially launched in France during 1986. At 31 December 2007, Decapeptyl^® had marketing authorizations in over 60 countries, including 25 in Europe. In 2007, 60.9% of Decapeptyl^® sales were generated in the 5 major European Countries. Debiopharm, which holds the patent to pamoate formulations of Decapeptyl^® has granted the Group an exclusive license to commercialise Decapeptyl^® within the European Union (outside Sweden) and in certain other countries. Debiopharm has also granted the Group a non-exclusive license to manufacture Decapeptyl^® within the European Union (outside Sweden) and in certain other countries (with Debiopharm nonetheless retaining the right to manufacture and supply Decapeptyl^® for its own purposes and those of its other licensees in territories not licensed to the Group).

About Ipsen

Ipsen is an innovation-driven international specialty pharmaceutical group with over 20 products on the market and a total worldwide staff of nearly 4,000. Its development strategy is based on a combination of specialty products, which are growth drivers, in targeted therapeutic areas (oncology, endocrinology and neuromuscular disorders), and primary care products which contribute significantly to its research financing. The location of its four Research & Development centres (Paris, Boston, Barcelona, London) and its peptide and protein engineering platform give the Group a competitive edge in gaining access to leading university research teams and highly qualified personnel. More than 700 people in R&D are dedicated to the discovery and development of innovative drugs for patient care. This strategy is also supported by an active policy of partnerships. In 2007, Research and Development expenditure was about €185 million, in excess of 20% of consolidated sales, which amounted to €920.5 million while total revenues amounted to €993.8 million. Ipsen’s shares are traded on Segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150). Ipsen’s shares are eligible to the "Service de Règlement Différé" ("SRD") and the Group is part of the SBF 120 index. For more information on Ipsen, visit our website at www.ipsen.com.

Forward-Looking Statements

The forward-looking statements, objectives and targets contained herein are based on the Group’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. Moreover, the targets described in this document were prepared without taking into account external growth assumptions, as announced on June 5, 2008 and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by the Group. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties. The Group does not commit nor gives any guarantee that it will meet the targets mentioned above. Furthermore, the Research and Development process involves several stages at each of which there is a substantial risk that the Group will fail to achieve its objectives and be forced to abandon its efforts in respect of a product in which it has invested significant sums. Therefore, the Group cannot be certain that favourable results obtained during pre-clinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. The Group expressly disclaims any obligation or undertaking to update or revise any forward looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. The Group’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers.


Source: Ipsen

[Read more!]

Pierre Fabre Castres - Peraudel — Company Profile

Institut de Recherche Pierre Fabre 17, Avenue Jean Moulin 81106 Castres Cedex France Tel.: +33 (0)5 63 71 42 00 Fax: +33 (0)5 63 35 66 29 Website: http://www.pierre-fabre.com/

Medical chemistry (central nervous system, cardio-vascular diseases).

Sector of activity
Research & Development

Branch of activity
Pharmacy

Personnel
232 Persons


Source: Pierre Fabre

[Read more!]

Pierre Fabre Ramonville - Ariane — Company Profile

Institut de Recherche Pierre Fabre Parc Technologique du Canal 3, rue Ariane 31527 Ramonville Cedex France Tel.: +33 (0)5 61 73 73 00 Fax: +33 (0)5 61 73 73 73 Website: http://www.pierre-fabre.com/

Innovation Development Center Pierre Fabre.

Sector of activity
Research & Development

Branch of activity
Pharmacy

Personnel
142 Persons


Source: Pierre Fabre

[Read more!]

MidiMed — Company Profile

MidiMed ZI du Bousquet 31360 Boussens France Tel.: +33 (0)5 61 97 69 69 Fax: +33 (0)5 61 87 17 59 Website: http://www.midimed.com/

MidiMed manufactures reagents for cell culture. We are committed to provide quality products and services to research laboratories and industrialists according to their needs.

• Standard and innovative culture media,
• Additives and antibiotics,
• Sera, albumins, plasma of most species and origins,
• Immunoglobulins,
• An innovative serum free range of products, "SafeCell".

MidiMed was created in July 2004; our 2000 m² factory located in Boussens, south of Toulouse offers you:

• Standard and customized Culture media.
• Serum Free media, based on containing vegetable extracts.
• Serums and plasma of most species and origins.
• Capacity to produce lots above 1000 litres.
• Additives and antibiotics for cell culture.
• Albumins and immunoglobulins.

The MidiMed company invested in several research projects in order to replace animal proteins by plant proteins.


Source: MidiMed

[Read more!]